BLUE
RNriannejar.bsky.social

Research has been ongoing for a vaccine that can handle unexpected new variants as well: mrdc.health.mil/index.cfm/me...#covid19#vaccine#SpFN#adjuvant#ALFQ

0
KBbachynski.bsky.social

Phase 1 trial of a “universal” Covid vaccine “demonstrates that vaccination with a self-assembling SARS-CoV-2 spike protein ferritin nanoparticle vaccine adjuvanted with ALFQ was well tolerated and broadly immunogenic against a broad panel of SARS-CoV-2 variants, subvariants, & other sarbecoviruses”

SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlle...
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlle...

SpFN/ALFQ was well tolerated and elicited robust and durable binding antibody and neutralising antibody titres against a broad panel of SARS-CoV-2 variants and other sarbecoviruses.

2
MVmarcveld.bsky.social

SARS-CoV-2 spike protein ferritin nanoparticle vaccine adjuvanted with ALFQ was well tolerated and broadly immunogenic against a broad panel of SARS-CoV-2 variants, subvariants, and other sarbecoviruses. 3/3

0
Ppastelbio.bsky.social

Random selection from Pastel's #proteomics resources page http://bit.ly/1J4g3CEhttps://github.com/aLFQ | aLFQ | R-package for estimat. abs. protein quant. from label-free LC-MS/MS data --- #proteomics #prot-other

0